Huy V. Huynh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huy V. Huynh has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Akhilesh Pandey
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication - Alan P. Fields
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA
1 shared publication - Anh T. Q. Cong
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, USA
1 shared publication - Cassandra M. Joiner
Department of Chemistry St. Olaf College 1520 St. Olaf Ave. Northfield MN 55057
1 shared publication Elizabeth S. Bruinsma
Department of Oncology, Mayo Clinic, Rochester, MN, USA
1 shared publication- Erin M. NewRingeisen
Department of Chemistry St. Olaf College 1520 St. Olaf Ave. Northfield MN 55057
1 shared publication
Latest Publications
- Open Access
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ
Protein kinase C (PKC) isozymes are ubiquitous kinases that direct diverse cellular pathways and are important drug targets for the treatment of cancer and neurological diseases. PKCs are auto-regulating enzymes governed by phospholipid and Ca 2+ signals via a mechanism that has remained enigmatic due to a paucity of structural information. Herein we present a series of structures of the full-length human PKCβI and PKCβII isozymes. These structures reveal the molecular basis by which PKCs maintain an auto-inhibited state, convert to a defined and ordered active conformation via a “lipid-lever” mechanism of allosteric activation, and how isoform-specific differences alter their allosteric regulatory mechanisms. We show that endoxifen, a recently identified PKCβI inhibitor, can alter the allosteric regulatory mechanism of PKCβI, providing a proof of concept for allosteric regulators of PKCs. Collectively, our data describe a foundational molecular model of second messenger-mediated allosteric regulation of PKCs that underpins PKC function, misregulation, and mechanisms of inhibition.
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMolecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ
Protein kinase C (PKC) isozymes are ubiquitous kinases that direct diverse cellular pathways and are important drug targets for the treatment of cancer and neurological diseases. PKCs are auto-regulating enzymes governed by phospholipid and Ca 2+ signals via a mechanism that has remained enigmatic due to a paucity of structural information. Herein we present a series of structures of the full-length human PKCβI and PKCβII isozymes. These structures reveal the molecular basis by which PKCs maintain an auto-inhibited state, convert to a defined and ordered active conformation via a “lipid-lever” mechanism of allosteric activation, and how isoform-specific differences alter their allosteric regulatory mechanisms. We show that endoxifen, a recently identified PKCβI inhibitor, can alter the allosteric regulatory mechanism of PKCβI, providing a proof of concept for allosteric regulators of PKCs. Collectively, our data describe a foundational molecular model of second messenger-mediated allosteric regulation of PKCs that underpins PKC function, misregulation, and mechanisms of inhibition.
- 25 November 2024
- Published by Wiley in ChemBioChem
- Vol. 26 (1) , e202400709
Photoactivatable O‐GlcNAc Transferase Library Enables Covalent Chemical Capture of Solvent‐Exposed TPR Domain Interactions
O‐linked N‐acetylglucosamine (O‐GlcNAc) transferase (OGT) is an essential, stress‐sensing enzyme responsible for adding the O‐GlcNAc monosaccharide to thousands of nuclear and cytoplasmic proteins to regulate cellular homeostasis. OGT substrates are found in almost all intracellular processes, and perturbations in protein O‐GlcNAc levels have been implicated in proteostatic diseases, such as cancers, metabolic disorders, and neurodegeneration. This broad disease activity makes OGT an attractive therapeutic target; however, the substrate diversity makes pan‐inhibition as a therapeutic strategy unfeasible. Rather, a substrate‐specific approach to targeting is more advantageous, but how OGT chooses its substrates remains poorly understood. Substrate specificity is controlled by the interactions between OGT's non‐catalytic tetratricopeptide repeat (TPR) domain, rather than its glycosyltransferase domain. OGT's TPR domain forms a 100 Å superhelical structure, containing a lumenal surface, known as the substrate‐binding surface, and a solvent‐exposed surface. To date, there are no tools to site‐selectively target regions of the domain and differentiate between the two binding surfaces. Here, we developed a library of recombinant OGT constructs containing site‐specifically incorporated photoactivatable unnatural amino acids (UAAs) along the solvent‐exposed surface of the TPR domain to covalently capture and map OGT's interactome.
- 25 November 2024
- Published by Wiley in ChemBioChem
- Vol. 26 (1) , e202400709
Photoactivatable O‐GlcNAc Transferase Library Enables Covalent Chemical Capture of Solvent‐Exposed TPR Domain Interactions
O‐linked N‐acetylglucosamine (O‐GlcNAc) transferase (OGT) is an essential, stress‐sensing enzyme responsible for adding the O‐GlcNAc monosaccharide to thousands of nuclear and cytoplasmic proteins to regulate cellular homeostasis. OGT substrates are found in almost all intracellular processes, and perturbations in protein O‐GlcNAc levels have been implicated in proteostatic diseases, such as cancers, metabolic disorders, and neurodegeneration. This broad disease activity makes OGT an attractive therapeutic target; however, the substrate diversity makes pan‐inhibition as a therapeutic strategy unfeasible. Rather, a substrate‐specific approach to targeting is more advantageous, but how OGT chooses its substrates remains poorly understood. Substrate specificity is controlled by the interactions between OGT's non‐catalytic tetratricopeptide repeat (TPR) domain, rather than its glycosyltransferase domain. OGT's TPR domain forms a 100 Å superhelical structure, containing a lumenal surface, known as the substrate‐binding surface, and a solvent‐exposed surface. To date, there are no tools to site‐selectively target regions of the domain and differentiate between the two binding surfaces. Here, we developed a library of recombinant OGT constructs containing site‐specifically incorporated photoactivatable unnatural amino acids (UAAs) along the solvent‐exposed surface of the TPR domain to covalently capture and map OGT's interactome.